DaVita (DVA) Proxy Filing summary

Executive summary

• Celebrated 25th anniversary with significant expansion in international markets, including new entries into Ecuador and Chile and deeper presence in Colombia.

• Achieved strong financial growth in 2024: operating income up 30%, adjusted operating income up 21%, and diluted EPS up 45%.

• Over 8,200 patients received kidney transplants, and 2,400+ employees advanced nursing degrees through internal programs.

• Teammate engagement score reached 84%, with 76,000+ employees globally.

• Board composition refreshed with the addition of Dennis Pullin as an independent director.

Voting matters and shareholder proposals

• Stockholders to vote on election of nine directors, ratification of KPMG LLP as auditor for 2025, and advisory approval of executive compensation.

• Board recommends voting FOR all proposals.

• Proxy access for director nominations available to shareholders meeting ownership and duration requirements.

Board of directors and corporate governance

• Board consists of nine nominees, eight of whom are independent under NYSE standards.

• Board diversity: 44% gender diverse, 22% racial/ethnic diversity, average tenure 5.8 years.

• Annual board and committee evaluations include written and live interviews.

• Independent non-executive chair and robust stockholder engagement practices.

• Board committees: Audit, Compensation, Nominating and Governance, Compliance and Quality—all with independent chairs.